Genistein attenuates retinal inflammation associated with diabetes by targeting of microglial activation

Ahmed Salah Ibrahim, Mamdouh M. El-Shishtawy, Alejandro Peña, Gregory I Liou

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Purpose: Diabetic retinopathy (DR) is associated with microglial activation and increased levels of inflammatory cytokines. Genistein, a tyrosine kinase inhibitor, has been shown to possess anti-inflammatory potential that so far untested in animal models of diabetes. The aims of this study are to evaluate the efficacy of genistein for alleviation of diabetesinduced retinal inflammation and also to gain insight into the molecular mechanisms involved therein by analyzing the effect of genistein on concomitant microglia activation in the diabetic retina and in isolated cells. Methods: Streptozotocin (STZ)-induced diabetic Sprague Dawley rats were used. After diabetes was established for two weeks a single intravitreal injection of genistein or vehicle was performed. Forty-eight hours later, rats were killed, their retinal and vitreal samples were processed for Quantitative Real Time-PCR (qRT-PCR) and Enzyme-linked immunosorbent assay (ELISA) analyses, respectively. For the in vitro study, isolated microglial cells from retinas of newborn rats were used. Results: mRNA as well as protein levels for tumor necrosis factor α (TNF-α), a robust marker of inflammation, were increased in the retina early in the course of diabetes. Moreover, diabetes resulted in elevation of ionized calcium binding adaptor molecule-1 (Iba1) mRNA, known to be upregulated in activated microglia. These effects of diabetes in retina were all reduced by intervention treatment with genistein. Using an in vitro bioassay, we demonstrated the release of TNF- α from microglia activated by glycated albumin, a risk factor for diabetic disorders. This inflammatory signal involves the activation of tyrosine kinase and its subsequent events, ERK and P38 MAPKs. Genistein represses the release of TNF- α and significantly inhibits ERK and P38 phosphorylation in activated microglial cells by acting as a tyrosine kinase inhibitor. Conclusions: These findings show genistein to be effective in dampening diabetes-induced retinal inflammation by interfering with inflammatory signaling (ERK and P38 MAPKs) that occurs in activated microglia. This beneficial effect of genistein may represent a new intervention therapy to modulate early pathological pathways long before the occurrence of vision loss among diabetics.

Original languageEnglish (US)
Pages (from-to)2033-2042
Number of pages10
JournalMolecular Vision
Volume16
StatePublished - Nov 18 2010

Fingerprint

Genistein
Inflammation
Microglia
Retina
Protein-Tyrosine Kinases
Tumor Necrosis Factor-alpha
p38 Mitogen-Activated Protein Kinases
Messenger RNA
Intravitreal Injections
Diabetic Retinopathy
Streptozocin
Biological Assay
Sprague Dawley Rats
Real-Time Polymerase Chain Reaction
Anti-Inflammatory Agents
Animal Models
Enzyme-Linked Immunosorbent Assay
Phosphorylation
Cytokines
Calcium

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Ibrahim, A. S., El-Shishtawy, M. M., Peña, A., & Liou, G. I. (2010). Genistein attenuates retinal inflammation associated with diabetes by targeting of microglial activation. Molecular Vision, 16, 2033-2042.

Genistein attenuates retinal inflammation associated with diabetes by targeting of microglial activation. / Ibrahim, Ahmed Salah; El-Shishtawy, Mamdouh M.; Peña, Alejandro; Liou, Gregory I.

In: Molecular Vision, Vol. 16, 18.11.2010, p. 2033-2042.

Research output: Contribution to journalArticle

Ibrahim, AS, El-Shishtawy, MM, Peña, A & Liou, GI 2010, 'Genistein attenuates retinal inflammation associated with diabetes by targeting of microglial activation', Molecular Vision, vol. 16, pp. 2033-2042.
Ibrahim, Ahmed Salah ; El-Shishtawy, Mamdouh M. ; Peña, Alejandro ; Liou, Gregory I. / Genistein attenuates retinal inflammation associated with diabetes by targeting of microglial activation. In: Molecular Vision. 2010 ; Vol. 16. pp. 2033-2042.
@article{8c8c868b504f4c4d93f871977d95f92f,
title = "Genistein attenuates retinal inflammation associated with diabetes by targeting of microglial activation",
abstract = "Purpose: Diabetic retinopathy (DR) is associated with microglial activation and increased levels of inflammatory cytokines. Genistein, a tyrosine kinase inhibitor, has been shown to possess anti-inflammatory potential that so far untested in animal models of diabetes. The aims of this study are to evaluate the efficacy of genistein for alleviation of diabetesinduced retinal inflammation and also to gain insight into the molecular mechanisms involved therein by analyzing the effect of genistein on concomitant microglia activation in the diabetic retina and in isolated cells. Methods: Streptozotocin (STZ)-induced diabetic Sprague Dawley rats were used. After diabetes was established for two weeks a single intravitreal injection of genistein or vehicle was performed. Forty-eight hours later, rats were killed, their retinal and vitreal samples were processed for Quantitative Real Time-PCR (qRT-PCR) and Enzyme-linked immunosorbent assay (ELISA) analyses, respectively. For the in vitro study, isolated microglial cells from retinas of newborn rats were used. Results: mRNA as well as protein levels for tumor necrosis factor α (TNF-α), a robust marker of inflammation, were increased in the retina early in the course of diabetes. Moreover, diabetes resulted in elevation of ionized calcium binding adaptor molecule-1 (Iba1) mRNA, known to be upregulated in activated microglia. These effects of diabetes in retina were all reduced by intervention treatment with genistein. Using an in vitro bioassay, we demonstrated the release of TNF- α from microglia activated by glycated albumin, a risk factor for diabetic disorders. This inflammatory signal involves the activation of tyrosine kinase and its subsequent events, ERK and P38 MAPKs. Genistein represses the release of TNF- α and significantly inhibits ERK and P38 phosphorylation in activated microglial cells by acting as a tyrosine kinase inhibitor. Conclusions: These findings show genistein to be effective in dampening diabetes-induced retinal inflammation by interfering with inflammatory signaling (ERK and P38 MAPKs) that occurs in activated microglia. This beneficial effect of genistein may represent a new intervention therapy to modulate early pathological pathways long before the occurrence of vision loss among diabetics.",
author = "Ibrahim, {Ahmed Salah} and El-Shishtawy, {Mamdouh M.} and Alejandro Pe{\~n}a and Liou, {Gregory I}",
year = "2010",
month = "11",
day = "18",
language = "English (US)",
volume = "16",
pages = "2033--2042",
journal = "Molecular Vision",
issn = "1090-0535",

}

TY - JOUR

T1 - Genistein attenuates retinal inflammation associated with diabetes by targeting of microglial activation

AU - Ibrahim, Ahmed Salah

AU - El-Shishtawy, Mamdouh M.

AU - Peña, Alejandro

AU - Liou, Gregory I

PY - 2010/11/18

Y1 - 2010/11/18

N2 - Purpose: Diabetic retinopathy (DR) is associated with microglial activation and increased levels of inflammatory cytokines. Genistein, a tyrosine kinase inhibitor, has been shown to possess anti-inflammatory potential that so far untested in animal models of diabetes. The aims of this study are to evaluate the efficacy of genistein for alleviation of diabetesinduced retinal inflammation and also to gain insight into the molecular mechanisms involved therein by analyzing the effect of genistein on concomitant microglia activation in the diabetic retina and in isolated cells. Methods: Streptozotocin (STZ)-induced diabetic Sprague Dawley rats were used. After diabetes was established for two weeks a single intravitreal injection of genistein or vehicle was performed. Forty-eight hours later, rats were killed, their retinal and vitreal samples were processed for Quantitative Real Time-PCR (qRT-PCR) and Enzyme-linked immunosorbent assay (ELISA) analyses, respectively. For the in vitro study, isolated microglial cells from retinas of newborn rats were used. Results: mRNA as well as protein levels for tumor necrosis factor α (TNF-α), a robust marker of inflammation, were increased in the retina early in the course of diabetes. Moreover, diabetes resulted in elevation of ionized calcium binding adaptor molecule-1 (Iba1) mRNA, known to be upregulated in activated microglia. These effects of diabetes in retina were all reduced by intervention treatment with genistein. Using an in vitro bioassay, we demonstrated the release of TNF- α from microglia activated by glycated albumin, a risk factor for diabetic disorders. This inflammatory signal involves the activation of tyrosine kinase and its subsequent events, ERK and P38 MAPKs. Genistein represses the release of TNF- α and significantly inhibits ERK and P38 phosphorylation in activated microglial cells by acting as a tyrosine kinase inhibitor. Conclusions: These findings show genistein to be effective in dampening diabetes-induced retinal inflammation by interfering with inflammatory signaling (ERK and P38 MAPKs) that occurs in activated microglia. This beneficial effect of genistein may represent a new intervention therapy to modulate early pathological pathways long before the occurrence of vision loss among diabetics.

AB - Purpose: Diabetic retinopathy (DR) is associated with microglial activation and increased levels of inflammatory cytokines. Genistein, a tyrosine kinase inhibitor, has been shown to possess anti-inflammatory potential that so far untested in animal models of diabetes. The aims of this study are to evaluate the efficacy of genistein for alleviation of diabetesinduced retinal inflammation and also to gain insight into the molecular mechanisms involved therein by analyzing the effect of genistein on concomitant microglia activation in the diabetic retina and in isolated cells. Methods: Streptozotocin (STZ)-induced diabetic Sprague Dawley rats were used. After diabetes was established for two weeks a single intravitreal injection of genistein or vehicle was performed. Forty-eight hours later, rats were killed, their retinal and vitreal samples were processed for Quantitative Real Time-PCR (qRT-PCR) and Enzyme-linked immunosorbent assay (ELISA) analyses, respectively. For the in vitro study, isolated microglial cells from retinas of newborn rats were used. Results: mRNA as well as protein levels for tumor necrosis factor α (TNF-α), a robust marker of inflammation, were increased in the retina early in the course of diabetes. Moreover, diabetes resulted in elevation of ionized calcium binding adaptor molecule-1 (Iba1) mRNA, known to be upregulated in activated microglia. These effects of diabetes in retina were all reduced by intervention treatment with genistein. Using an in vitro bioassay, we demonstrated the release of TNF- α from microglia activated by glycated albumin, a risk factor for diabetic disorders. This inflammatory signal involves the activation of tyrosine kinase and its subsequent events, ERK and P38 MAPKs. Genistein represses the release of TNF- α and significantly inhibits ERK and P38 phosphorylation in activated microglial cells by acting as a tyrosine kinase inhibitor. Conclusions: These findings show genistein to be effective in dampening diabetes-induced retinal inflammation by interfering with inflammatory signaling (ERK and P38 MAPKs) that occurs in activated microglia. This beneficial effect of genistein may represent a new intervention therapy to modulate early pathological pathways long before the occurrence of vision loss among diabetics.

UR - http://www.scopus.com/inward/record.url?scp=78149472989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78149472989&partnerID=8YFLogxK

M3 - Article

C2 - 21042558

AN - SCOPUS:78149472989

VL - 16

SP - 2033

EP - 2042

JO - Molecular Vision

JF - Molecular Vision

SN - 1090-0535

ER -